Primary large B-cell lymphoma of the central nervous system: A reappraisal of CD5-positive cases based on clinical, pathological, and molecular evaluation
Corresponding Author
Seiji Yamada
Division of Analytical Pathology, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University School of Medicine, Toyoake, Japan
Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Correspondence Seiji Yamada, MD, PhD, Research Promotion Headquarters, Division of Analytical Pathology, Oncology Innovation Center, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Email: [email protected]
Search for more papers by this authorAkira Satou
Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan
Search for more papers by this authorYuta Tsuyuki
Center for Clinical Pathology, Fujita Health University Hospital, Toyoake, Japan
Search for more papers by this authorSachiko Iba
Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan
Search for more papers by this authorYuka Okumura
Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
Search for more papers by this authorEri Ishikawa
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Search for more papers by this authorHideaki Ito
Department of Pathology, Aichi Medical University, Nagakute, Japan
Search for more papers by this authorYasunori Kogure
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
Search for more papers by this authorNaoe Goto
Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan
Search for more papers by this authorMotoki Tanikawa
Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Search for more papers by this authorKazuyuki Shimada
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Search for more papers by this authorTetsuya Tsukamoto
Division of Analytical Pathology, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University School of Medicine, Toyoake, Japan
Search for more papers by this authorKennosuke Karube
Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
Search for more papers by this authorHideaki Yokoo
Department of Human Pathology, Gunma University Graduate School of Medicine, Gunma, Japan
Search for more papers by this authorKeisuke Kataoka
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
Search for more papers by this authorAkihiro Tomita
Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan
Search for more papers by this authorMitsuhito Mase
Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Search for more papers by this authorShigeo Nakamura
Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
Search for more papers by this authorCorresponding Author
Seiji Yamada
Division of Analytical Pathology, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University School of Medicine, Toyoake, Japan
Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Correspondence Seiji Yamada, MD, PhD, Research Promotion Headquarters, Division of Analytical Pathology, Oncology Innovation Center, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
Email: [email protected]
Search for more papers by this authorAkira Satou
Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan
Search for more papers by this authorYuta Tsuyuki
Center for Clinical Pathology, Fujita Health University Hospital, Toyoake, Japan
Search for more papers by this authorSachiko Iba
Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan
Search for more papers by this authorYuka Okumura
Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
Search for more papers by this authorEri Ishikawa
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Search for more papers by this authorHideaki Ito
Department of Pathology, Aichi Medical University, Nagakute, Japan
Search for more papers by this authorYasunori Kogure
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
Search for more papers by this authorNaoe Goto
Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan
Search for more papers by this authorMotoki Tanikawa
Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Search for more papers by this authorKazuyuki Shimada
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Search for more papers by this authorTetsuya Tsukamoto
Division of Analytical Pathology, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University School of Medicine, Toyoake, Japan
Search for more papers by this authorKennosuke Karube
Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
Search for more papers by this authorHideaki Yokoo
Department of Human Pathology, Gunma University Graduate School of Medicine, Gunma, Japan
Search for more papers by this authorKeisuke Kataoka
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
Search for more papers by this authorAkihiro Tomita
Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan
Search for more papers by this authorMitsuhito Mase
Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Search for more papers by this authorShigeo Nakamura
Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
Search for more papers by this authorAbstract
CD5 expression is seen in 5%–10% of de novo diffuse large B-cell lymphomas (DLBCLs). Primary large B-cell lymphoma of the central nervous system (PCNS-LBCL) also exhibits CD5 expression in a minority of cases, however, clinicopathological and molecular features remain largely unclarified. Here we present the clinical, molecular, and pathological features of 11 CD5-positive (+) PCNS-LBCL cases, occupying 6.7% of all 165 PCNS-LBCLs diagnosed in our institutions. While CD5+ systemic DLBCL has been recognized as a distinctive subgroup showing an aggressive clinical course, no obvious differences were found between CD5+ and CD5-negative subgroups among the present CNS patients clinically. MYD88 p.L265P and CD79B p.Y196 mutations were detected in eight (73%) and seven (64%) cases, respectively, supporting previous reports. Notably, the microenvironmental immune cells were universally PD-L1/CD274-positive, and the higher levels tended to present favorable overall survival, as already evidenced in the PCNS-LBCL series. In contrast, neoplastic PD-L1/CD274 expression was undetectable in all cases. Indeed, no structural variations or copy number alterations involving PD-1 ligands were detected by targeted-capture sequencing and fluorescence in situ hybridization. While further studies are warranted, we may have confirmed similarity between PCNS-LBCLs and intravascular large B-cell lymphomas from a molecular standpoint.
CONFLICT OF INTEREST STATEMENT
None declared.
REFERENCES
- 1Deckert M, Batchelor T, Ferry JA, et al. Primary diffuse large B-cell lymphoma of the CNS. In: WHO classification of tumours, central nervous system tumours. 5th edn. Lyon: International Agency for Research on Cancer; 2021. p. 351–355.
- 2Kluin PM, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edn. Lyon: International Agency for Research on Cancer; 2017. p. 300–302.
- 3Ball MK, Morris JM, Wood AJ, Meyer FB, Kaszuba MC, Raghunathan A. Ventricle-predominant primary CNS lymphomas: clinical, radiological and pathological evaluation of five cases and review of the literature. Brain Tumor Pathol. 2020; 37: 22–30.
- 4Schlegel U. Review: primary CNS lymphoma. Ther Adv Neurol Disord. 2009; 2: 93–104.
- 5Kipps TJ. The CD5 B cell. Adv Immunol. 1989; 47: 117–185.
- 6Antin JH, Emerson SG, Martin P, Gadol N, Ault KA. Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies. J Immunol. 1986; 136: 505–510.
- 7Fischer M, Klein U, Küppers R. Molecular single-cell analysis reveals that CD5-positive peripheral blood B cells in healthy humans are characterized by rearranged Vkappa genes lacking somatic mutation. J Clin Invest. 1997; 100: 1667–1676.
- 8Hardy RR, Hayakawa K. Development and physiology of Ly-1 B and its human homolog, Leu-1 B. Immunol Rev. 1986; 93: 53–80.
- 9Kantor AB. The development and repertoire of B-1 cells (CD5 B cells). Immunol Today. 1991; 12: 389–391.
- 10Kasaian MT, Ikematsu H, Casali P. CD5+ B lymphocytes. Exp Biol Med. 1991; 197: 226–241.
- 11Youinou P, Jamin C, Lydyard PM. CD5 expression in human B-cell populations. Immunol Today. 1999; 20: 312–316.
- 12Lydyard PM, Jewell AP, Jamin C, Youinou PY. CD5 B cells and B-cell malignancies. Curr Opin Hematol. 1999; 6: 30–36.
- 13Zeng W, Fu K, Quintanilla-Fend L, Lim M, Ondrejka S, Hsi ED. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol. 2012; 36: 214–219.
- 14Chuang WY, Chang H, Shih LY, Wang PN, Chang YS, Lin TL, et al. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Arch. 2015; 467: 571–582.
- 15Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015; 6: 5615–5633.
- 16Stein H, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon: International Agency for Research on Cancer; 2008. p. 233–237.
- 17Yamaguchi M. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002; 99: 815–821.
- 18Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008; 19: 1921–1926.
- 19Niitsu N, Okamoto M, Tamaru J, Yoshino T, Nakamura N, Nakamura S, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010; 21: 2069–2074.
- 20Na HY, Choe JY, Shin SA, Kim HJ, Han JH, Kim HK, et al. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: high incidence of BCL2 and MYC double-expressors. PLoS One. 2019; 14:e0224247.
- 21Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood. 2018; 132: 1561–1567.
- 22Shimada K, Kinoshita T, Naoe T, Nakamura S. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol. 2009; 10: 895–902.
- 23Imai H, Shimada K, Shimada S, Abe M, Okamoto M, Kitamura K, et al. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma. Pathol Int. 2009; 59: 431–437.
- 24Ishikawa E, Kato S, Shimada K, Tanaka T, Suzuki Y, Satou A, et al. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells. Cancer Med. 2018; 7: 6051–6063.
- 25Ishikawa E, Nakamura M, Shimada K, Tanaka T, Satou A, Kohno K, et al. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma. J Gastroenterol. 2020; 55: 39–50.
- 26Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci. 2002; 99: 12293–12297.
- 27Iwai Y. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2004; 17: 133–144.
- 28Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011; 17: 4232–4244.
- 29Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013; 19: 3462–3473.
- 30Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, et al. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood. 2016; 128: 1374–1381.
- 31Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik JH, et al. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology. 2016; 68: 1079–1089.
- 32Hans CP. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275–282.
- 33Tsuyuki Y, Ishikawa E, Kohno K, Shimada K, Ohka F, Suzuki Y, et al. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system. Neuropathology. 2021; 41: 99–108.
- 34Yamada S, Muto J, Iba S, Shiogama K, Tsuyuki Y, Satou A, et al. Primary central nervous system lymphomas with massive intratumoral hemorrhage: clinical, radiological, pathological, and molecular features of six cases. Neuropathology. 2021; 41: 335–348.
- 35Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, Kogure Y, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019; 33: 1687–1699.
- 36Yamashita D, Shimada K, Kohno K, Kogure Y, Kataoka K, Takahara T, et al. PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: a clinicopathological study of 50 cases. Pathol Int. 2020; 70: 513–522.
- 37Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013; 48: 452–458.
- 38Takeuchi T, Yamaguchi M, Kobayashi K, Miyazaki K, Tawara I, Imai H, et al. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Cancer. 2017; 123: 1166–1173.
- 39King RL, Goodlad JR, Calaminici M, Dotlic S, Montes-Moreno S, Oschlies I, et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch. 2020; 476: 647–665.
- 40Yamada S, Ishida Y, Matsuno A, Yamazaki K. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma. 2015; 56: 2141–2145.
- 41Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016; 42: 279–290.
- 42Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, et al. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv. 2019; 3: 375–383.
- 43Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018; 378: 1396–1407.
- 44Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Med. 2018; 24: 679–690.
- 45Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020; 135: 1759–1771.
- 46Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, et al. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood. 2021; 137: 1491–1502.
- 47Suzuki Y, Kohno K, Matsue K, Sakakibara A, Ishikawa E, Shimada S, et al. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy. Cancer Med. 2020; 9: 4768–4776.
- 48Gupta GK, Jaffe ES, Pittaluga S. A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features. Histopathology. 2019; 75: 282–286.
- 49Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg ML, Mannisto S, et al. PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica. 2018; 103: 1908–1914.
- 50McCord R, Bolen CR, Koeppen H, Kadel EE, Oestergaard MZ, Nielsen T, et al. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019; 3: 531–540.
